Vitro Biopharma, Inc.

Formerly OTC: VODG
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 19 pages Appendix B Form of Senior Secured Convertible Note
12/34/56
EX-10.47
from S-1/A 3 pages Amendment to 6% Unsecured Promissory Note
12/34/56
EX-10.46
from S-1/A 3 pages Amendment to 4% Unsecured Promissory Note
12/34/56
EX-10.41
from S-1/A 10 pages Strictly Confidential
12/34/56
EX-10.40
from S-1/A 6 pages Consulting Agreement
12/34/56
EX-10.38
from 10-K 11 pages Convertible Note and Warrant Purchase Agreement
12/34/56
EX-10.37
from 10-K 3 pages Convertible Promissory Note
12/34/56
EX-10.36
from 10-K 3 pages Certain Identified Information, Marked by [***], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Memorandum of Understanding by and Between Vitro Biopharma, Inc. and Dr. Jack Zamora
12/34/56
EX-10.35
from 10-K 18 pages Certain Identified Information, Marked by [***], Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Supply Agreement
12/34/56
EX-10.34
from 10-K 4 pages Standstill Agreement
12/34/56
EX-10.33
from 10-K 9 pages Mutual Release and Settlement Agreement
12/34/56
EX-10.3
from 8-K 3 pages January 11th, 2023 Tom Ohrt Re: Chief Financial Officer Offer Compensation and Benefits
12/34/56
EX-10.2
from 8-K 10 pages Mutual Release and Settlement Agreement
12/34/56
EX-10.1
from 8-K 6 pages Consulting Agreement
12/34/56
EX-10.42
from S-1/A 2 pages Material contract
12/34/56
EX-10.41
from S-1/A 10 pages Strictly Confidential
12/34/56
EX-10.6
from 8-K 6 pages Consulting Agreement
12/34/56
EX-10.5
from 8-K 15 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 23 pages Appendix D Form of Security Agreement
12/34/56
EX-10.3
from 8-K 20 pages Appendix C Form of Warrant
12/34/56